NASDAQ:ATNX - Athenex Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.86
  • Forecasted Upside: 269.52 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.75
▼ -0.23 (-5.78%)

This chart shows the closing price for ATNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Athenex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNX

Analyst Price Target is $13.86
▲ +269.52% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Athenex in the last 3 months. The average price target is $13.86, with a high forecast of $33.00 and a low forecast of $5.00. The average price target represents a 269.52% upside from the last price of $3.75.

This chart shows the closing price for ATNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Athenex. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/8/2021SVB LeerinkReiterated RatingHoldHigh
7/6/2021OppenheimerReiterated RatingHoldHigh
7/6/2021Needham & Company LLCReiterated RatingHoldHigh
5/9/2021SVB LeerinkReiterated RatingHoldLow
3/9/2021Truist SecuritiesReiterated RatingBuy ➝ Hold$29.00 ➝ $6.00Low
3/8/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$22.00 ➝ $5.00N/A
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$30.00 ➝ $7.00N/A
3/8/2021OppenheimerReiterated RatingOutperform ➝ Market PerformN/A
3/2/2021Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$9.00 ➝ $33.00Medium
3/2/2021OppenheimerDowngradeOutperform ➝ Market PerformMedium
3/2/2021TruistDowngradeBuy ➝ Hold$6.00Medium
3/1/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$22.00 ➝ $5.00High
3/1/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $7.00High
3/1/2021LaidlawLower Price TargetBuy$38.00 ➝ $13.00Medium
3/1/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
2/10/2021Evercore ISIInitiated CoverageOutperformLow
11/5/2020Needham & Company LLCLower Price TargetBuy$30.00 ➝ $27.00Medium
10/26/2020SVB LeerinkInitiated CoverageOutperform$22.00Low
9/1/2020Royal Bank of CanadaBoost Price TargetOutperform$31.00 ➝ $33.00Low
6/22/2020Needham & Company LLCReiterated RatingBuy$30.00Medium
6/7/2020OppenheimerInitiated CoverageBuy$23.00High
5/13/2020OppenheimerReiterated RatingBuy$23.00Medium
5/7/2020OppenheimerReiterated RatingBuy$23.00Low
4/9/2020Needham & Company LLCReiterated RatingBuy$30.00N/A
12/16/2019Needham & Company LLCReiterated RatingBuy$30.00High
12/6/2019SunTrust BanksInitiated CoverageBuy$28.00High
11/19/2019Royal Bank of CanadaReiterated RatingBuy$31.00Medium
7/30/2019SunTrust BanksBoost Price TargetBuy$30.00Low
6/25/2019Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $31.00Low
5/2/2019CIBCInitiated CoverageOutperform ➝ Outperform$20.00Medium
5/2/2019OppenheimerInitiated CoverageOutperform$20.00High
3/29/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$20.00Medium
3/12/2019Royal Bank of CanadaReiterated RatingOutperformMedium
11/15/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$24.00 ➝ $15.00High
10/25/2018LADENBURG THALM/SH SHInitiated CoverageBuy$27.00High
3/6/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$30.00High
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$22.20 ➝ $23.00Low
1/17/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$20.00High
10/18/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$22.20N/A
9/19/2017LaidlawInitiated CoverageBuy$36.00Medium
9/18/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$25.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$35.00High
7/10/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$20.00Low
(Data available from 7/23/2016 forward)
Athenex logo
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Read More

Today's Range

Now: $3.75
Low: $3.75
High: $4.05

50 Day Range

MA: $4.58
Low: $3.75
High: $5.13

52 Week Range

Now: $3.75
Low: $3.66
High: $15.24

Volume

1,285,506 shs

Average Volume

3,914,205 shs

Market Capitalization

$350.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Athenex?

The following Wall Street analysts have issued reports on Athenex in the last year: Evercore ISI, JPMorgan Chase & Co., Laidlaw, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, SVB Leerink LLC, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for ATNX.

What is the current price target for Athenex?

7 Wall Street analysts have set twelve-month price targets for Athenex in the last year. Their average twelve-month price target is $13.86, suggesting a possible upside of 269.5%. Royal Bank of Canada has the highest price target set, predicting ATNX will reach $33.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $5.00 for Athenex in the next year.
View the latest price targets for ATNX.

What is the current consensus analyst rating for Athenex?

Athenex currently has 6 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATNX, but not buy more shares or sell existing shares.
View the latest ratings for ATNX.

What other companies compete with Athenex?

How do I contact Athenex's investor relations team?

Athenex's physical mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company's listed phone number is 716-427-2950 and its investor relations email address is [email protected] The official website for Athenex is www.athenex.com.